Nicox Welcomes a New Board Member
In a significant development for the company, Nicox SA, a prominent international ophthalmology firm, has appointed Christine Placet to its Board of Directors. This appointment signals a new chapter in the company’s strategic leadership, focused on enhancing its mission in ocular health.
Christine Placet: A Strong New Addition
Christine Placet brings a wealth of experience to her new role, having served as CFO of Theranexus and previously held CEO positions at both Horama and Trophos. Her extensive background in the biotech industry underscores her leadership skills and strategic insight, making her an excellent addition to the Nicox board.
Significant Change in Leadership
Michele Garufi, co-founder and former CEO of Nicox, has decided to step down from his position on the Board. Garufi has devoted over 25 years to fostering growth and innovation at Nicox, steering the company through its early stages and advancing its vision of enhancing ocular care solutions.
Strategic Direction for the Future
This announcement underscores Nicox’s commitment to adapting and thriving in a competitive environment. The newly restructured board aims to harness diverse expertise to effectively navigate the company’s strategic goals.
Damian Marron's Vision for Nicox
Damian Marron, the current Chairman, expressed his enthusiasm for Placet's appointment, highlighting their collaborative history at Trophos. He emphasized the importance of her extensive biotech experience, especially as the company prepares for critical advancements with its promising compound, NCX 470.
A Tribute to Michele Garufi
Garufi's legacy at Nicox is marked by innovation and strong leadership. His dedication has been vital to the company’s long-term objective of developing effective treatments for eye conditions. As Nicox transitions into a new era, Garufi is confident that the new leadership will continue to inspire further breakthroughs.
Christine Placet's Track Record
Placet’s career features a notable period at Trophos, where she led the company to a successful acquisition by Roche, showcasing her strategic business acumen. Since then, she has been at the forefront of innovative ventures in biotechnology, making her a valuable asset to Nicox as it advances its clinical developments.
About Nicox
Nicox SA specializes in developing innovative treatments aimed at improving ocular health. Their lead product, NCX 470, is designed to tackle significant challenges faced by glaucoma patients, highlighting Nicox’s forward-thinking approach to eye care.
Frequently Asked Questions
What positions did Christine Placet hold before joining Nicox?
Christine Placet previously served as CFO of Theranexus and CEO of both Horama and Trophos.
Who does Christine Placet replace on the Board?
Christine Placet replaces Michele Garufi, who has stepped down after a long tenure at Nicox.
What is NCX 470?
NCX 470 is Nicox's leading compound aimed at reducing intraocular pressure for glaucoma treatment.
How long did Michele Garufi serve at Nicox?
Michele Garufi served at Nicox for over 25 years before stepping down from his position.
Where is Nicox headquartered?
Nicox is headquartered in Sophia Antipolis, France, and is actively listed on Euronext Paris with the ticker symbol ALCOX.
